Yao Wang

11PUBLICATIONS
21CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 08, 2026
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.

|Apr 15, 2026
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

|Mar 18, 2026
DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling.

Xinran Ma, Yang Zhang, Yao Wang

|Mar 10, 2026
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.

Fuxin Han, Yadi Zhong, Chuan Tong

|Jan 18, 2026
MCT1 inhibition remodels the tumor immune microenvironment for enhanced cancer immunotherapy.

Yipeng Zhang, Chun Liu, Fuxin Han

|Jul 04, 2025
CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation.

Qi Zhu, Jiajia Li, Nan Liu

Pageof 2

Frequent Collaborators

10 joint publications

Weidong Han

7 joint publications

Zhiqiang Wu

3 joint publications

Fuxin Han

2 joint publications

Yelei Guo